PTH1R and osteoporosis: Two FDA‐approved bone anabolic osteoporosis medications target the parathyroid hormone receptor (PTH1R): teriparatide, recombinant parathyroid hormone (PTH[1‐34]),(1) and abaloparatide, an analogue of PTH related‐peptide (PTHrP[1‐34]).(2)